INTERGRATED DIA.H DL 0,25 Aktie

Integrated Diagnostics reports a 37% revenue increase for 2025 to $2.07 billion and an adjusted net income of 1.26 billion EGP (+79%). Gross and EBITDA margins improved to 42.7% and 34.9%, respectively, while Egypt contributed 84.6% of revenue. The company plans around 200 new outlets in Egypt and Saudi Arabia and is focusing on higher-value diagnostics and digital integration. Geopolitical risks in the region weigh on investor sentiment; the stock rose only 0.32% after the results. » Altro su de.investing.com

Integrated Diagnostics recorded 41% revenue growth in the first nine-month period of 2025, driven by a 10% higher test volume and a 28% higher average revenue per test. Gross margin rose to 43% and EBITDA margin to 35%, while adjusted net profit increased by 119%. The company opened 103 new branches in Egypt and plans expansion into Saudi Arabia with planned Capex of $20m (2026–2030). Despite the strong figures, the share price fell by 3.03%, indicating mixed investor sentiment or uncertainties about the future. » Altro su de.investing.com